By the conclusion of this video, you will be able to
describe the design of common types of membrane
permeability assays. You will be able
to relate the in vitro assay results to
in vivo PK properties. Finally, you will
be able to list the transporter proteins most likely to affect absorption and distribution of
potential drugs. Membranes are vital in biology for allowing compartmentalization
within an organism. Membranes also happened
to pose a barrier for both drug absorption
and distribution. Understanding how well a
molecule can cross membranes, a property called
membrane permeability, is critically important
for the drug-hunting team. In vitro membrane
permeability assessment tools like PAMPA, which is based
on an artificial membrane, or Caco-2 cells, which are a human epithelial
colorectal cell line, and the canine
kidney cell line or MDCK are commonly used to
quantify permeability. The permeability of a
molecule is frequently measured using a
two-chambered apparatus. The two chambers are separated by a permeable support layered with an artificial lipid
membrane or cell monolayer. The test compound is placed
in the donor chamber and its appearance in the
acceptor chamber is measured. The appearance and the acceptor
chamber as a function of time is related to the
permeability of the compound. Highly permeable
compounds appear in the acceptor chamber
at a faster rate than poorly permeable compounds. The rate of appearance of
the compound is known as the apparent permeability
and is often reported in centimeters
per second times 10^6. The apparent permeability
can be related to the extent to which
a compound can permeate a cell or the extent
to which it crosses a barrier epithelium like the intestine or
blood-brain barrier. This is typically done by establishing a
relationship between the apparent permeability
and in vivo measurement, such as that shown
on this slide for apparent permeability and
the human fraction absorbed. This correlation can be used
to estimate the fraction absorbed f_a in human based
on apparent permeability. The product of the
fraction absorbed along with the fraction escaping gut and hepatic metabolism, abbreviated as f_g
and f_h respectively, constitutes the drug's
bioavailability F. Permeability assays are
used to select compounds for further studies by enabling project teams to
identify compounds with sufficient permeability to
have a suitably high fraction absorbed in the gut and enable
adequate oral exposure. In such cases, high
permeability and a correspondingly
higher fraction absorbed is frequently desired. Permeability assays also provide insight into the potential
mechanism of clearance, where highly permeable
molecules are predominantly cleared
by metabolism and poorly permeable
molecules may also be cleared by transporters
in the liver and kidney. Molecules often cross membranes
by passive diffusion. The transporter proteins often also play an important role. The transporter mediated
transmembrane flux of a compound can be measured using
cells that express one or more transporters
of interest, and the movement of the
compound is quantified in much the same way as the
permeability assays. These black circles are meant to represent a possible
transporter protein. Some key transporters
of interest to a drug-hunting team are the multi-drug
resistance proteins, multi-drug resistant
associated proteins, organic anionic
transporting polypeptides, breast cancer
resistance protein, and organic cation transporters. Correlation of in
vitro transporter data to in vivo properties is challenging due to
broad tissue and cell type distribution of
specific transporters. This can result in the
need for multiple in vitro models by tissue
and by transporter. Correlation is further
challenging in that most in vitro models do not adequately replicate
the in vivo condition. To date, translating
transporter data from in vitro to in vivo has yielded mixed results in the field with no commonly
accepted practice. One example, however, of a correlative success is
that relationship between in vitro MDR1 transporter activity and in vivo brain penetration. MDR1 limits brain
penetration of drugs, so high MDR1 efflux
ratio against the compound with the brain indication
may be undesirable. This type of
information can help the selection of
compounds most likely to have favorable in vivo
pharmacokinetic properties. We have now described in vitro membrane permeability
assays and how the results can assist in
their prediction of in vivo absorption and
distribution properties. We have also listed some common transporter proteins that facilitate
transmembrane flux.